A. Bettini

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)

K. Zaman, A. Stathis, O. Michielin, 2022, Cancers.

1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

C. Britschgi, D. Betticher, M. Joerger, 2020 .

Journal Pre-proof UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN) Real-life

S. Schokrpur, A. Addeo, S. Häfliger, 2022 .

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

S. Peters, C. Britschgi, D. Betticher, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer — A Multicentre Single-Arm Phase II Trial

S. Peters, C. Britschgi, D. Betticher, 2021 .

The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study

M. Levivier, C. Tuleasca, L. Schiappacasse, 2019, Journal of Neuro-Oncology.

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

S. Peters, C. Britschgi, D. Betticher, 2016 .